WHO backs Glaxo's Rotarix for mass vaccination
GlaxoSmithKline Plc's vaccine Rotarix, designed to prevent gastroenteritis caused by rotavirus in children, has been endorsed as suitable for use by UN agencies by the World Health Organisation.
bdnews24.com News Service
bdnews24.com
Published :
13 Feb 2007, 12:35 PM
Updated :
17 Aug 2022, 02:25 PM
LONDON, Feb 13 (bdnews24.com/Reuters) - GlaxoSmithKline Plc's vaccine Rotarix, designed to prevent gastroenteritis caused by rotavirus in children, has been endorsed as suitable for use by UN agencies by the World Health Organisation.
The British-based drugmaker said on Tuesday it was the first such vaccine to win so-called prequalification status from the international health body.
The move certifies the vaccine's quality, safety and efficacy, allowing agencies like the Pan American Health Organisation, UNICEF and others to use it in mass vaccination programmes.
Glaxo's vaccines head Jean Stephenne said Rotarix would be offered at tiered prices, with the lowest prices reserved for the public sector in the world's poorest countries.
Rotavirus is the most common cause of severe diarrhoea in children worldwide.
bdnews24.com/srs/1724 hrs